These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21124075)

  • 1. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
    Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
    Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
    Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
    Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
    Bhat R; Dempe S; Dinsart C; Rommelaere J
    Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
    Bhat R; Rommelaere J
    BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
    Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
    Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
    Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
    BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
    Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
    Viruses; 2021 May; 13(6):. PubMed ID: 34071585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
    Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
    Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
    Bretscher C; Marchini A
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
    Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
    Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic parvoviruses as cancer therapeutics.
    Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
    Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
    Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
    Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.
    Schäfer TE; Knol LI; Haas FV; Hartley A; Pernickel SCS; Jády A; Finkbeiner MSC; Achberger J; Arelaki S; Modic Ž; Schröer K; Zhang W; Schmidt B; Schuster P; Haferkamp S; Doerner J; Gebauer F; Ackermann M; Kvasnicka HM; Kulkarni A; Bots STF; Kemp V; Hawinkels LJAC; Poetsch AR; Hoeben RC; Ehrhardt A; Marchini A; Ungerechts G; Ball CR; Engeland CE
    EBioMedicine; 2024 Jul; 105():105219. PubMed ID: 38941955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-faceted mechanism of parvoviral oncosuppression.
    Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
    Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
    Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
    J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
    Akladios C; Aprahamian M
    Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity.
    Raykov Z; Grekova S; Leuchs B; Aprahamian M; Rommelaere J
    Int J Cancer; 2008 Jun; 122(12):2880-4. PubMed ID: 18360875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.